TAG:
laboratory company
IMPATH Has a Buyer: Genzyme Pays $215 Mil
By Robert Michel | From the Volume XI No. 4 – March 15, 2004 Issue
CEO SUMMARY: Two unexpected things happened in IMPATH’s Chapter 11 bankruptcy action. First, it attracted a buyer willing to pay the premium price of $215 million for its assets. Second, the buyer was not another laboratory company. Rather, it is a new entrant into the oncology diagnost…
LabOne in Cincinnati: Watch Events Unfold
By Robert Michel | From the Volume XI No. 3 – February 23, 2004 Issue
CEO SUMMARY: It’s another example of a commercial laboratory taking over the laboratory assets of a multi-hospital consolidated laboratory. Will LabOne manage these assets and get more growth, more cost savings, and more profit? If this happens, it will mark the third time in r…
“February 2, 2004 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XI No. 2 – February 2, 2004 Issue
Changes are afoot in the national market for anatomic pathology services. At AmeriPath, Inc., the search is on for a new CEO. Current Chairman and CEO, James C. New retired, effective February 1. The company has commenced the search for a new CEO. New had been with AmeriPath since it…
Who’s Buying Labs? Activity Shifts Down
By Robert Michel | From the Volume X No. 17 – December 22, 2003 Issue
CEO SUMMARY: As the number of independent clinical laboratories dwindles, most remaining owners seem content to continue building their business—at least until a buyer makes them an offer “they can’t refuse.” Acquisitions of pathology group practices were also few in number during…
“Waiver of Charges”: What Makes It Work
By Robert Michel | From the Volume X No. 16 – December 1, 2003 Issue
CEO SUMMARY: Little-used in the 1990s, when laboratory test ordering and billing practices were under intense scrutiny by federal regulators, the strategy of “free testing” is popping up in more regions around the country. To comply with compliance guidelines, labs using this strategy g…
Bio-Reference Labs An Example Of How Regional Labs Can Grow
By Robert Michel | From the Volume X No. 15 – November 10, 2003 Issue
IT’ S QUARTERLY EARNINGS TIME, which makes it possible to evaluate trends in the laboratory services marketplace by looking at the performance of public laboratory companies. Because of their large size and market dominance, the two national laboratory companies are closely watched to see how they…
Brazil’s Lab Industry Gathers in Rio de Janeiro
By Robert Michel | From the Volume X No. 13 – September 29, 2003 Issue
CEO SUMMARY: Healthcare in Brazil remains a free market and thousands of clinical laboratories exist to fill the demand. However, there are early indications that commercial laboratories in Brazil may be on the verge of the same tidal wave of lab acquisitions and consolidation that was ex…
Online Distance Training Helps Labs Recruit & Retain More MTs
By Robert Michel | From the Volume X No. 9 – July 7, 2003 Issue
CEO SUMMARY: One surprise about online distance learning (ODL) programs for medical technologists (MT) is that even small hospital laboratories can use them to recruit and train more MTs. Across the United States, a growing number of labs are experiencing a shortage of MTs in their local …
Specialty Laboratories, IMPATH, Roche, Abbott Laboratories, Celera Diagnostics
By Robert Michel | From the Volume X No. 6 – May 5, 2003 Issue
SPECIALTY LABORATORIES RESTORING STABILITY IN SPECIMEN VOLUME IT’S NO SURPRISE THAT COMPETITORS of Specialty Laboratories, Inc. have been willing to spread a variety of rumors about the laboratory company, given its well-publicized troubles with government regulators last …
“May 5, 2003 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume X No. 6 – May 5, 2003 Issue
There are rumors coming from the West Coast that government laboratory regulators are targeting at least one laboratory company for some significant violations. Because allegations of compliance violations by the government can severely damage a lab company’s reputation, there is a tight lid on infor…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized